Insights from cardiovascular outcome trials with novel antidiabetes agents: what have we learned? An industry perspective (Q38586898)

4 September 2017

Insights from cardiovascular outcome trials with novel antidiabetes agents: what have we learned? An industry perspective (English)

1 reference

4 September 2017

Boaz Hirshberg

1

1 reference

PubMed ID

26370698

4 September 2017

Arie Katz

series ordinal

2

1 reference

4 September 2017

1 November 2015

1 reference

4 September 2017

Current diabetes report

1 reference

4 September 2017

15

1 reference

4 September 2017

87

1 reference

4 September 2017

11

1 reference

https://scigraph.springernature.com/pub.10.1007/s11892-015-0663-9

4 September 2017

0 references

cites work

Trends in cardiovascular disease risk factors in individuals with and without diabetes mellitus in the Framingham Heart Study

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0663-9

Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0663-9

Comparative determinants of 4-year cardiovascular event rates in stable outpatients at risk of or with atherothrombosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0663-9

Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0663-9

Rosiglitazone: a European regulatory perspective.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0663-9

Cardiovascular outcome studies with novel antidiabetes agents: scientific and operational considerations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0663-9

Diabetes clinical trials: helped or hindered by the current shift in regulatory requirements?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0663-9

A systematic assessment of cardiovascular outcomes in the saxagliptin drug development program for type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0663-9

Assessment of the cardiovascular safety of saxagliptin in patients with type 2 diabetes mellitus: pooled analysis of 20 clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0663-9

Assessing the cardio-cerebrovascular safety of vildagliptin: meta-analysis of adjudicated events from a large Phase III type 2 diabetes population

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0663-9

Cardiovascular safety of sitagliptin in patients with type 2 diabetes mellitus: a pooled analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0663-9

Cardiovascular safety with linagliptin in patients with type 2 diabetes mellitus: a pre-specified, prospective, and adjudicated meta-analysis of a phase 3 programme

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0663-9

Cardiovascular safety of linagliptin in type 2 diabetes: a comprehensive patient-level pooled analysis of prospectively adjudicated cardiovascular events

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0663-9

Cardiovascular safety of the dipetidyl peptidase-4 inhibitor alogliptin in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0663-9

Dipeptidyl peptidase-4 inhibitors and cardiovascular risk: a meta-analysis of randomized clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0663-9

Cardiovascular safety of exenatide BID: an integrated analysis from controlled clinical trials in participants with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0663-9

Effects of glucagon-like peptide-1 receptor agonists on cardiovascular risk: a meta-analysis of randomized clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0663-9

Cardiovascular outcome trials of glucose-lowering drugs or strategies in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0663-9

Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0663-9

Efficacy and safety of saxagliptin in older participants in the SAVOR-TIMI 53 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0663-9

Heart failure, saxagliptin, and diabetes mellitus: observations from the SAVOR-TIMI 53 randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0663-9

Alogliptin after acute coronary syndrome in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0663-9

Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0663-9

Dipeptidyl peptidase-4 inhibitors and heart failure: a meta-analysis of randomized clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0663-9

Glucose-lowering drugs or strategies and cardiovascular outcomes in patients with or at risk for type 2 diabetes: a meta-analysis of randomised controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0663-9

Dipeptidyl peptidase-4 inhibitors and cardiovascular outcomes: meta-analysis of randomized clinical trials with 55,141 participants

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0663-9

Sitagliptin use in patients with diabetes and heart failure: a population-based retrospective cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0663-9

Hospitalisation for heart failure and mortality associated with dipeptidyl peptidase 4 (DPP-4) inhibitor use in an unselected population of subjects with type 2 diabetes: a nested case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0663-9

Glucose control and vascular complications in veterans with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0663-9

Effects of intensive glucose lowering in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0663-9

10-year follow-up of intensive glucose control in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0663-9

Follow-up of glycemic control and cardiovascular outcomes in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11892-015-0663-9

Heart failure and dipeptidyl peptidase-4 inhibitors

21 January 2018

1 reference

12 December 2020

Cardiovascular safety of liraglutide assessed in a patient-level pooled analysis of phase 2—3 liraglutide clinical development studies

1 reference

12 December 2020

Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes and moderate or severe renal impairment: observations from the SAVOR-TIMI 53 Trial

1 reference

12 December 2020

Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes

1 reference

12 December 2020

10.1007/S11892-015-0663-9

Identifiers

DOI

1 reference

PubMed ID

26370698

Dimensions Publication ID

4 September 2017

0 references

1 reference

PubMed ID

26370698